tiprankstipranks
Advertisement
Advertisement
Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion
PremiumCompany AnnouncementsCardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion
2M ago
Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network
Premium
The Fly
Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network
2M ago
Cardiol Therapeutics Expands U.S. Phase III MAVERIC Trial Network as Enrollment Reaches 75%
Premium
Company Announcements
Cardiol Therapeutics Expands U.S. Phase III MAVERIC Trial Network as Enrollment Reaches 75%
2M ago
Cardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care Conference
PremiumCompany AnnouncementsCardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care Conference
4M ago
Cardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart Failure
Premium
Company Announcements
Cardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart Failure
5M ago
Cardiol Therapeutics Secures $14.85 Million Bought-Deal Unit Financing
Premium
Company Announcements
Cardiol Therapeutics Secures $14.85 Million Bought-Deal Unit Financing
5M ago
Cardiol Therapeutics trading halted, news pending
PremiumThe FlyCardiol Therapeutics trading halted, news pending
6M ago
Cardiol Therapeutics Reaches 50% Enrollment in Pivotal Phase III MAVERIC Trial for Recurrent Pericarditis
Premium
Company Announcements
Cardiol Therapeutics Reaches 50% Enrollment in Pivotal Phase III MAVERIC Trial for Recurrent Pericarditis
6M ago
Cardiol Therapeutics: Strong Buy Rating Backed by Promising CardiolRx Trial Results and Strategic Growth Potential
Premium
Ratings
Cardiol Therapeutics: Strong Buy Rating Backed by Promising CardiolRx Trial Results and Strategic Growth Potential
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100